Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 6c; Offers FY22 Revenue Guidance
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $28.61 +0.21%
EPS Growth %: -266.7%
Financial Fact:
Basic (in Shares): -23.01M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -266.7%
Financial Fact:
Basic (in Shares): -23.01M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $43.7 million versus the consensus estimate of $42.3 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2022 revenue of $185-195 million, versus the consensus of $187.6 million.
For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
- UBS cuts KOSPI target by nearly 10% to reflect higher rates
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
